George Elston serves as the Executive Vice President and Chief Financial Officer at Eyepoint Pharmaceuticals Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. In his role, Elston is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, and investor relations. His strategic leadership has been instrumental in guiding Eyepoint through critical growth phases, ensuring the company's financial stability and supporting its mission to address unmet needs in ophthalmology. Prior to joining Eyepoint Pharmaceuticals, Elston held several high-level financial positions at various healthcare and biotech companies. He has a proven track record of driving financial performance and operational efficiency. Notably, he served as CFO at Hyperion Therapeutics, where he played a key role in the company's successful IPO and subsequent acquisition by Horizon Pharma. Elston's extensive experience in the biotech sector, combined with his strong financial acumen, has made him a valuable asset to Eyepoint Pharmaceuticals. Elston's achievements extend beyond his professional roles. He is recognized for his contributions to the broader financial community, often speaking at industry conferences and contributing to discussions on financial strategy in the biotech sector. His commitment to excellence and innovation in finance has helped Eyepoint Pharmaceuticals navigate the complex landscape of drug development and commercialization, positioning the company for continued success in the competitive field of ophthalmic treatments.